康希诺：预计2025年净利2450万元-2900万元 同比扭亏为盈

Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of the parent company between 24.5 million and 29 million yuan in 2025, marking a turnaround from losses in the previous year [1] Group 1 - The company is focusing on innovation as its core strategy and emphasizes the importance of commercialization [1] - The revenue from the first quadrivalent meningococcal vaccine, Manhaixin, continues to grow steadily [1]